Loading stock data…
Cencora (COR)
$281.65-4.48 (-1.57%)
Market ClosedLast close Jun 29
Cencora, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cencora, Inc. in the Healthcare sector is trading at $281.65 with a market capitalization of $54.4B. Wall Street consensus targets $351.00 (12 analysts), implying a +24.6% move over the next 12 months. The stock is currently 25% below its 52-week high of $377.54, remaining 12.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $78.36B↓ | $85.93B↑ | $83.73B↑ | $80.66B↑ | $75.45B |
| Gross Profit | $3.59B↑ | $3.07B↑ | $2.95B↑ | $2.91B↓ | $3.06B |
| Operating Income | $1.36B↑ | $1.02B↑ | $945.94M↓ | $980.24M↓ | $1.20B |
| Net Income | $1.64B↑ | $559.65M↑ | -$339.70M↓ | $687.40M↓ | $717.87M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home hea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$54.38B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.62%
ROE
Elite ROE. Management converts capital into profit efficiently.
75.01%
Volume
Today's trading volume
781,537
Recent News
Is McKesson Corporation (MCK) A Good Stock To Buy Now?
Is MCK a good stock to buy? We came across a bullish thesis on McKesson Corporation on r/ValueInvesting by OnTheStreetwithLou. In this article, we will summarize the bulls’ thesis on MCK. McKesson Corporation’s share was trading at $763.91 as of June 23rd. MCK’s trailing and forward P/E were 19.41 and 16.81 respectively according to Yahoo Finance. McKesson […]
Cencora (COR) Stock After Recent Pullback And DCF Valuation Gap
If you are wondering whether Cencora stock is priced for opportunity or already reflects its strengths, the current setup invites a closer look at what investors are really paying for. Cencora shares last closed at US$286.13, with the stock up 5.5% over the past week and 6.2% over the past month, while still showing a 15.6% decline year to date and a 3.9% decline over the past year. These shorter term moves sit alongside a longer 3 year return of 53.8% and a 5 year return of 158.3%. This...
Cencora (COR) Launches Nucleus Pilot As Verizon Executive Joins As CHRO
Cencora (NYSE:COR) has launched a multi-site pilot of its upgraded Nucleus inventory management solution for specialty physician practices. The pilot focuses on improving medication workflow efficiency and inventory visibility across participating sites. The company has appointed Samantha Hammock, formerly of Verizon, as Chief Human Resources Officer, succeeding Silvana Battaglia. These developments reflect operational and leadership changes that may affect Cencora's specialty care...
3 Big Reasons to Love Cencora (COR)
Over the past six months, Cencora’s stock price fell to $287.06. Shareholders have lost 15.8% of their capital, which is disappointing considering the S&P 500 has climbed by 6.2%. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.